Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...

A cardiologist's assertion that Ozempic is a "cardiometabolic medicine" rather than just a weight-loss trend has sparked ...

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Weight-loss jabs, such as Ozempic and Wegovy, have revolutionised the way we treat obesity in humans, and scientists now want ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular ...